Professor, Neurology-Brigham and Women's Hospital, Harvard Medical School

Neurology

Reisa A. Sperling, MD works in the field of Neurology. He studied medicine at Harvard Medical School. Harvard Medical School is one of the top medical schools in the US. Harvard Medical School is ranked 1 in research and 12 in primary care medicine He received 1 awards: "Super Doctor". Reisa A. Sperling, MD has written publications. He has 105 publications published with PubMed. The lastest paper is: 'The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials.' Doctor Reisa A. Sperling, MD is registered with Medicare and accepts Medicare payments.

Publications

---

• Physical Activity Is Positively Associated with Episodic Memory in Aging.
• CD33 modulates TREM2: convergence of Alzheimer loci.
• Dopamine transporter availability in clinically normal aging is associated with individual differences in white matter integrity.
• Tau PET imaging in aging and early Alzheimer's Disease.
• Amyloid-β deposition in mild cognitive impairment is associated with increased hippocampal activity, atrophy and clinical progression.
• Building a roadmap for developing combination therapies for Alzheimer's Disease.
• Predicting Reduction of Cerebrospinal Fluid β-Amyloid 42 in Cognitively Healthy Controls.
• Depressive Symptoms and Biomarkers of Alzheimer's Disease in Cognitively Normal Older Adults.
• Tracking Early Decline in Cognitive Function in Older Individuals at Risk for Alzheimer Disease Dementia: The Alzheimer's Disease Cooperative Study Cognitive Function ...
• Relationships between default-mode network connectivity, medial temporal lobe structure, and age-related memory deficits.
• Partial volume correction in quantitative amyloid imaging.
• Charting a path toward combination therapy for Alzheimer's Disease.
• Title (78 characters): A TREM1 variant alters the accumulation of Alzheimer-related amyloid pathology.
• The Evolution of Preclinical Alzheimer's Disease: Implications for Prevention Trials.
• Regional cortical thinning predicts worsening apathy and hallucinations across the Alzheimer Disease spectrum.
• Multiple Brain Markers are Linked to Age-Related Variation in Cognition.
• Subjective cognitive concerns, episodic memory, and the APOE ε4 allele.
• Functional connectivity in autosomal dominant and late-onset Alzheimer Disease.
• Synergistic Effect of β-Amyloid and Neurodegeneration on Cognitive Decline in Clinically Normal Individuals.
• The Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline.
• Symptom onset in autosomal dominant Alzheimer Disease: A systematic review and meta-analysis.
• Flexible modulation of network connectivity related to cognition in Alzheimer's Disease.
• Regional Fluorodeoxyglucose Metabolism and Instrumental Activities of Daily Living across the Alzheimer's Disease Spectrum.
• Vascular Disease and Risk Factors are Associated With Cognitive Decline in the Alzheimer Disease Spectrum.
• Development of a Psychometrically Equivalent Short Form of the Face-Name Associative Memory Exam for use Along the Early Alzheimer's Disease Trajectory.
• Task-induced brain activity patterns in type 2 diabetes: a potential biomarker for cognitive decline.
• Amyloid Deposition Is Linked to Aberrant Entorhinal Activity among Cognitively Normal Older Adults.
• Regional Cortical Thinning and Cerebrospinal Biomarkers Predict Worsening Daily Functioning Across the Alzheimer's Disease Spectrum.
• Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer's Disease.
• Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study.
• The A4 Study: Stopping AD Before Symptoms Begin?
• Mild to moderate Alzheimer Dementia with insufficient neuropathological changes.
• Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's Disease.
• Promising developments in neuropsychological approaches for the detection of preclinical Alzheimer's Disease: a selective review.
• Regional variability of imaging biomarkers in autosomal dominant Alzheimer's Disease.
• Preclinical trials in autosomal dominant AD: Implementation of the DIAN-TU trial.
• The pattern of atrophy in familial Alzheimer Disease: Volumetric MRI results from the DIAN study.
• Functional connectivity in Alzheimer's Disease: measurement and meaning.
• Impaired default network functional connectivity in autosomal dominant Alzheimer Disease.
• Differential functional response in the posteromedial cortices and hippocampus to stimulus repetition during successful memory encoding.
• In vivo characterization of the early states of the amyloid-beta network.
• Age and apolipoprotein E genotype influence rate of cognitive decline in nondemented elderly.
• Imaging markers for Alzheimer Disease: Which vs how.
• CD33 Alzheimer's Disease locus: altered monocyte function and amyloid biology.
• MR Imaging Features of Amyloid-Related Imaging Abnormalities.
• The parahippocampal gyrus links the default-mode cortical network with the medial temporal lobe memory system.
• New ELISAs with high specificity for soluble oligomers of amyloid ?-protein detect natural A? oligomers in human brain but not CSF.
• Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's Disease dementia, mild cognitive impairment, and normal aging.
• Apolipoprotein E ?4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer Disease.
• Preclinical Alzheimer Disease-the challenges ahead.
• Cognitive Profile of Amyloid Burden and White Matter Hyperintensities in Cognitively Normal Older Adults.
• Cortical atrophy in presymptomatic Alzheimer's Disease presenilin 1 mutation carriers.
• The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects.
• Activities of daily living: where do they fit in the diagnosis of Alzheimer's Disease?
• Functional MRI of Mnemonic Networks Across the Spectrum of Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
• Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals.
• Validation of the Face Name Associative Memory Exam in cognitively normal older individuals.
• Tracking Cognitive Change over 24 Weeks with Longitudinal Functional Magnetic Resonance Imaging in Alzheimer's Disease.
• Clinical impact of updated diagnostic and research criteria for Alzheimer's Disease.
• Testing the right target and right drug at the right stage.
• Specific Subjective Memory Complaints in Older Persons May Indicate Poor Cognitive Function.
• Alzheimer's Disease: implications of the updated diagnostic and research criteria.
• Failure to Modulate Attentional Control in Advanced Aging Linked to White Matter Pathology.
• Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer's Association Research Roundtable Workgroup.
• Neuroimaging markers for the prediction and early diagnosis of Alzheimer's Disease dementia.
• Test-retest reliability of memory task functional magnetic resonance imaging in Alzheimer Disease clinical trials.
• Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's Disease.
• Toward defining the preclinical stages of Alzheimer's Disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic gu...
• Neuronal dysfunction and disconnection of cortical hubs in non-demented subjects with elevated amyloid burden.
• Failure of repetition suppression and memory encoding in aging and Alzheimer's Disease.
• Developing a global strategy to prevent Alzheimer's Disease: Leon Thal Symposium 2010.
• Age and amyloid-related alterations in default network habituation to stimulus repetition.
• Independent Component Analysis-Based Classification of Alzheimer's Disease MRI Data.
• Defaulting on the default network: increased risk for Dementia.
• Autosomal-dominant Alzheimer's Disease: a review and proposal for the prevention of Alzheimer's Disease.
• Amyloid-β associated cortical thinning in clinically normal elderly.
• Intrinsic connectivity between the hippocampus and posteromedial cortex predicts memory performance in cognitively intact older individuals.
• A single ascending dose study of bapineuzumab in patients with Alzheimer Disease.
• Functional alterations in memory networks in early Alzheimer's Disease.
• Intrinsic interhemispheric hippocampal functional connectivity predicts individual differences in memory performance ability.
• Cognition, reserve, and amyloid deposition in normal aging.
• Evidence of altered posteromedial cortical FMRI activity in subjects at risk for Alzheimer Disease.
• Disruption of functional connectivity in clinically normal older adults harboring amyloid burden.
• Neural correlates of metamemory: a comparison of feeling-of-knowing and retrospective confidence judgments.
• Amyloid deposition is associated with impaired default network function in older persons without Dementia.
• The cortical signature of Alzheimer's Disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in ...
• Neural basis for recognition confidence in younger and older adults.
• Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's Disease.
• Impaired medial temporal repetition suppression is related to failure of parietal deactivation in Alzheimer Disease.
• Age-related memory impairment associated with loss of parietal deactivation but preserved hippocampal activation.
• Clinical prediction of Alzheimer Disease dementia across the spectrum of mild cognitive impairment.
• Evidence for a specific role of the anterior hippocampal region in successful associative encoding.
• Alterations in memory networks in mild cognitive impairment and Alzheimer's Disease: an independent component analysis.
• Understanding metamemory: neural correlates of the cognitive process and subjective level of confidence in recognition memory.
• Hippocampal and neocortical activation during repetitive encoding in older persons.
• Neuroimaging biomarkers for clinical trials of Disease-modifying therapies in Alzheimer's Disease.
• Dissociating confidence and accuracy: functional magnetic resonance imaging shows origins of the subjective memory experience.
• Medial temporal lobe function and structure in mild cognitive impairment.
• Use of IQ-adjusted norms to predict progressive cognitive decline in highly intelligent older individuals.
• Maternal Dementia age at onset in relation to amyloid burden in non-demented elderly offspring.
• The Feasibility of At-Home iPad Cognitive Testing For Use in Clinical Trials.
• Ethical challenges in preclinical Alzheimer's Disease observational studies and trials: Results of the Barcelona summit.
• Suspected non-Alzheimer Disease pathophysiology - concept and controversy.
• Different partial volume correction methods lead to different conclusions: An (18)F-FDG-PET study of aging.

Schools

---

• Harvard Medical School

• Brigham and Women39s Hospital

• Harvard Longwood Neurology

Conditions Treated

---

• Alzheimer's Disease
• Concussion
• Dementia
• Epilepsy
• View All

Doctors Specialties

---

• Neurology

Accepted Insurances

---

• Choice Plus POS II
• Blue Card PPO
• BlueConnect HMO
• Blue with Managed Care Behavioral Health HMO
• Preferred Blue PPO
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• Open Access Plus
• First Health (Coventry Health Care) PPO
• Choice Care PPO
• MultiPlan PPO
• PHCS Network PPO
• Tufts PPO
• Choice Plus POS
• Navigate HMO
• Navigate POS
• Options PPO

Awards

---

• Super Doctor

Education

---

• Boston Children's Hospital
• Brigham and Women's Hospital
• Harvard Medical School

Hospital

---

• Massachusetts General Hospital
• Brigham and Women's Hospital

Drug Facts

---

NPI NUMBER		1265422638
NPPES Provider LastName		SPERLING
NPPES Provider FirstName		REISA
NPPES Provider ZIPCode		021156110
NPPES Provider State		MA
Specialty Description		Neurology
Total Claim Count		89.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1265422638
Last Name Of The Provider	SPERLING
First Name Of The Provider	REISA
View All

Similar Doctors

---

	Dr. Anne M. Young, MD This Doctor is OpenDoctor Recommended.
	Dr. Aaron Izenberg, MD
	Dr. Katherine T. Dawson, MD This Doctor is OpenDoctor Recommended.
	Dr. Emily A. Gertsch, MD This Doctor is OpenDoctor Recommended.
	Dr. Asim Haque, MD
	Dr. Ruchira M. Jha, MD This Doctor is OpenDoctor Recommended.
	Dr. Bonnie P. Hersh, MD This Doctor is OpenDoctor Recommended.
	Dr. Kathy Chuang, MD This Doctor is OpenDoctor Recommended.
	Dr. John H. Growdon, MD This Doctor is OpenDoctor Recommended.
	Dr. Dean P. Sarco, MD
	Dr. David K. Urion, MD This Doctor is OpenDoctor Recommended.
	Dr. Tobias Loddenkemper, MD This Doctor is OpenDoctor Recommended.
	Dr. Sana Syed, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog